Related Experiment Video
Updated: Jun 7, 2026
04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
Medical therapy for obesity.
1Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA, USA. George.Bray@pbrc.edu
The Mount Sinai Journal of Medicine, New York
|October 21, 2010
Summary
Effective obesity treatment requires reversing energy imbalance. Adherence to calorie reduction is key, regardless of diet macronutrient composition. Current obesity drugs offer modest weight loss, with new combinations emerging.
Area of Science:
- Metabolism and Endocrinology
- Pharmacology
- Public Health
Background:
- Obesity stems from a sustained positive energy imbalance.
- Numerous dietary approaches exist for obesity treatment, all yielding weight loss.
- No single macronutrient composition has demonstrated superiority for weight loss diets.
Purpose of the Study:
- To review the effectiveness of different dietary strategies for obesity.
- To examine the role of adherence in weight loss success.
- To discuss current and emerging pharmacological treatments for obesity.
Main Methods:
- Literature review of dietary interventions for obesity.
- Analysis of studies on macronutrient composition and weight loss.
- Overview of existing obesity medications (Orlistat, Sibutramine) and their mechanisms.
- Discussion of novel obesity drug combinations.
Main Results:
- All diets lead to weight loss, with adherence to calorie reduction being the primary factor.
- Orlistat provides modest weight loss by inhibiting intestinal lipase.
- Sibutramine, a serotonin-norepinephrine reuptake inhibitor, carries cardiovascular risks and has faced market suspension.
- New combination therapies for obesity are under development.
Conclusions:
- Dietary adherence, not macronutrient composition, is crucial for successful obesity management.
- Pharmacological interventions offer additional options, but require careful consideration of risks and benefits.
- Future obesity treatments may involve combination drug therapies.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Behavior Therapy
Behavior therapy incorporates diverse techniques rooted in classical conditioning principles to address maladaptive behaviors and anxiety disorders. These methods aim to reduce avoidance behaviors, foster adaptive coping mechanisms, and alter associations between stimuli and responses, making them effective in a wide range of therapeutic contexts.
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...